HC Wainwright Reaffirms “Buy” Rating for X4 Pharmaceuticals (NASDAQ:XFOR)

X4 Pharmaceuticals (NASDAQ:XFOR)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a research note issued to investors on Friday, Benzinga reports. They currently have a $5.00 price target on the stock.

Separately, Cantor Fitzgerald reissued an “overweight” rating and issued a $5.00 price target on shares of X4 Pharmaceuticals in a report on Friday, May 31st.

X4 Pharmaceuticals Stock Performance

XFOR stock opened at $0.58 on Friday. The company has a market capitalization of $97.41 million, a P/E ratio of -0.83 and a beta of 0.40. The company has a 50-day simple moving average of $1.02 and a 200 day simple moving average of $0.99. X4 Pharmaceuticals has a fifty-two week low of $0.57 and a fifty-two week high of $2.06. The company has a quick ratio of 3.71, a current ratio of 3.71 and a debt-to-equity ratio of 52.92.

X4 Pharmaceuticals (NASDAQ:XFOR) last posted its quarterly earnings data on Tuesday, May 7th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.09). Sell-side analysts predict that X4 Pharmaceuticals will post -0.55 earnings per share for the current fiscal year.

Institutional Investors Weigh In On X4 Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the business. Bain Capital Life Sciences Investors LLC lifted its holdings in X4 Pharmaceuticals by 6.0% in the 4th quarter. Bain Capital Life Sciences Investors LLC now owns 16,915,784 shares of the company’s stock valued at $14,184,000 after acquiring an additional 955,196 shares during the last quarter. Kingdon Capital Management L.L.C. raised its holdings in X4 Pharmaceuticals by 76.0% during the 4th quarter. Kingdon Capital Management L.L.C. now owns 3,473,683 shares of the company’s stock worth $2,913,000 after buying an additional 1,500,000 shares during the period. SG Americas Securities LLC raised its holdings in X4 Pharmaceuticals by 38.8% during the 4th quarter. SG Americas Securities LLC now owns 47,668 shares of the company’s stock worth $40,000 after buying an additional 13,328 shares during the period. GSA Capital Partners LLP acquired a new stake in X4 Pharmaceuticals during the 3rd quarter worth about $678,000. Finally, Price T Rowe Associates Inc. MD raised its holdings in X4 Pharmaceuticals by 46.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 39,307 shares of the company’s stock worth $55,000 after buying an additional 12,514 shares during the period. 72.03% of the stock is owned by institutional investors and hedge funds.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.